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Background: Haemorrhoids (piles) are a very common condition seen in surgical clinics. After exclusion of more
sinister causes of haemorrhoidal symptoms (rectal bleeding, perianal irritation and prolapse), the best option for
treatment depends upon persistence and severity of the symptoms. Minor symptoms often respond to
conservative treatment such as dietary fibre and reassurance. For more severe symptoms treatment such as rubber
band ligation may be therapeutic and is a very commonly performed procedure in the surgical outpatient setting.
Surgery is usually reserved for those who have more severe symptoms, as well as those who do not respond to
non-operative therapy; surgical techniques include haemorrhoidectomy and haemorrhoidopexy. More recently,
haemorrhoidal artery ligation has been introduced as a minimally invasive, non destructive surgical option.
There are substantial data in the literature concerning efficacy and safety of 'rubber band ligation including multiple
comparisons with other interventions, though there are no studies comparing it to haemorrhoidal artery ligation. A
recent overview has been carried out by the National Institute for Health and Clinical Excellence which concludes
that current evidence shows haemorrhoidal artery ligation to be a safe alternative to haemorrhoidectomy and
haemorrhoidopexy though it also highlights the lack of good quality data as evidence for the advantages of
the technique.
Methods/design: The aim of this study is to establish the clinical effectiveness and cost effectiveness of
haemorrhoidal artery ligation compared with conventional rubber band ligation in the treatment of people with
symptomatic second or third degree (Grade II or Grade III) haemorrhoids.
Design: A multi-centre, parallel group randomised controlled trial.
Outcomes: The primary outcome is patient-reported symptom recurrence twelve months following the
intervention. Secondary outcome measures relate to symptoms, complications, health resource use, health related
quality of life and cost effectiveness following the intervention.
Participants: 350 patients with grade II or grade III haemorrhoids will be recruited in surgical departments in up to
14 NHS hospitals.
Randomisation: A multi-centre, parallel group randomised controlled trial. Block randomisation by centre will be
used, with 175 participants randomised to each group.
Discussion: The results of the research will help inform future practice for the treatment of grade II and III
haemorrhoids.
Trial Registration: ISRCTN41394716
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Haemorrhoidal tissue, which forms the ‘anal cushions’, is
a normal component of the anal canal and is composed
predominantly of vascular tissue, supported by smooth
muscle and connective tissue. Haemorrhoids result from
enlargement of the haemorrhoidal plexus and patho-
logical changes in the anal cushions. They are common,
affecting as many as 1 in 3 of the population [1]. Ap-
proximately 23,000 haemorrhoidal operations were car-
ried out in England in 2004/5 [2] and the prevalence
may be even higher in professionally active people.
Repeated visits to hospital for therapy represent a signifi-
cant disruption to the personal and working lives for this
population in particular.
Treatment is dictated by the degree of symptoms and
the degree of prolapse, and ranges from dietary advice to
rubber band ligation (RBL) in the outpatient department,
to an operation under general or regional anaesthetic.
Although RBL is cheap, it has a high recurrence rate and
patients often require further visits to the outpatient de-
partment for repeat banding before exploring surgical
options [3]. Although there are some variations (such as
ligasure haemorrhoidectomy), surgery is commonly trad-
itional "open" haemorrhoidectomy (OH) or a stapled
haemorrhoidopexy (SH); both require an anaesthetic.
OH is associated with considerable post-operative dis-
comfort, sometimes necessitating overnight hospital stay
and a delay in return to normal activity, but has a low
recurrence rate; SH has a slightly higher recurrence rate
but is carried out as a day case and patients return to
normal activity more quickly [4]. An alternative treat-
ment is haemorrhoidal artery ligation (HAL), which also
requires an anaesthetic, but is thought to enable even
quicker return to normal activity. Recurrence rates are
reportedly similar to SH but complication rates are
lower [5].
There are substantial data in the literature concerning
efficacy and safety of RBL including multiple compari-
sons with other interventions [6-12]. Recurrence varies
from 11% to over 50%. This broad range probably
reflects the definition of recurrence (patient symptoms
or clinical appearance), the grade of haemorrhoids trea-
ted (grade I know prolapse; grade II spontaneously redu-
cible prolapse; grade III prolapse requiring manual
reduction; and grade IV un-reducible prolapse), the
number of treatments and/or the intensity and length of
follow up. In most studies, the incidence of recurrence is
more than 30% and appears greatest for grade III hae-
morrhoids. Pain is common for a few hours following
RBL and occasionally patients experience pain so severe
as to require admission to hospital (around 1% [3]),
bleeding (3-4%, sometimes necessitating further treat-
ment [10]) and vaso-vagal symptoms (3% [13]). There
have also been rare incidences of blood transfusion[14,15] and severe pelvic sepsis with a few instances
leading death [13]. Recurrences can be treated by re-
banding or by surgical intervention.
Although HAL requires an anaesthetic, evidence sug-
gests a recovery similar to RBL but an effectiveness that
approaches the more intensive surgical options. The
substantial data concerning effectiveness includes one
recent systematic review [5], three Randomised Control
Trials (RCTs) [16-18], one non-randomised trial [19]
and over 20 case series. A recent overview has been car-
ried out by the National Institute for Health and Clinical
Excellence (NICE), which concludes that current evi-
dence shows it to be a safe alternative to OH or SH [20],
this is summarised below.
 In terms of efficacy, studies with more than 1 year
follow up suggest bleeding, pain on defecation and
prolapse (surrogates of recurrent symptoms) in 10%,
9% and 11% of patients respectively
 Regarding safety, post-operative haemorrhage
requiring intervention (readmission, transfusion,
reoperation or correction of coagulopathy) was
reported in less than 1.2%, haemorrhoidal
thrombosis was seen in less than 3.5% and fissure
formation in less than 2.1%
 The data from the three RCTs comparing HAL with
SH and OH is difficult to combine, but efficacy
seems similar for all procedures, with OH perhaps
being superior in treating prolapse, although it is
unclear if a "pexy" stitch was used in the HAL cases
to reduce prolapse. OH appears to lead to the most
post-operative pain and longest recovery. There are
conflicting results as to whether the HAL technique
results in less pain compared with SH.
Complications were also more frequent in the OH
group but occurred at a similar frequency when SH
and HAL were employed.
Both the systematic review and the NICE overview
highlight the lack of good quality data as evidence for
the advantages of the technique; most data is from case
series. Even the RCTs have significant methodological
drawbacks that make them subject to selection, perform-
ance, attrition and detection bias. Indeed none of the
studies are powered to reach any meaningful conclusion.
There are no existing studies that compare HAL with
RBL.Methods/design
The trial will be co-ordinated from the Clinical Trials
Research Unit (CTRU) in Sheffield School of Health
and Related Research (ScHARR). Delegated study staff
located at individual centres will identify and consent
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three groups:
1. Patients presenting to the surgical outpatient clinic
(SOPC) with symptomatic haemorrhoids that do not
require further tests. This group will be identified by
the clinical team from the GP referral letter and a
patient information sheet sent to them prior to their
clinic appointment. If they are willing to participate
they will be consented and randomised when they
attend the appointment.
2. Patients presenting to the SOPC with symptomatic
haemorrhoids that require further tests to exclude
other diagnoses. This group will be identified by the
clinician at the clinic appointment and given a
patient information sheet. They will undergo the
necessary outpatient tests (usually endoscopy) and if
negative (i.e. the symptoms are due to haemorrhoids)
they will be contacted by the research nurse prior to
attending their follow-up clinic appointment. They
will then be randomised and consented when they
re-attend the clinic.
3. Patients who return to SOPC following one
unsuccessful RBL. They will be identified by the
clinician at their first clinic appointment (when they
have RBL) and given a patient information sheet.
They will be contacted prior to a follow-up
appointment (usually six weeks after treatment) by a
research nurse. If they remain symptomatic and are
willing to participate, they will be consented and
randomised when they re-attend.
Thus, in each group, there is opportunity to provide
the patient information sheet prior to a clinic appoint-
ment. Patients with investigations excluding pathologies
other than haemorrhoids, and all those who have under-
gone rubber band ligation, will be contacted by the re-
search nurse before the planned follow up clinic to
ascertain whether they meet entry criteria and are inter-
ested in entering the trial. They will then be seen by the
consultant and research nurse in clinic where recruit-
ment and randomisation will take place.
After consent, participants will be individually rando-
mised to HAL or RBL in equal proportion at all centres
using a remote, web-based randomisation system.
Data will be collected to establish which patients have
further treatment for recurrent symptoms or complica-
tions following their initial procedure. This will be
achieved at the six week clinic visit following the inter-
vention and by interrogating hospital records, asking the
patients’ consultants, writing to patients’ GPs and ques-
tioning the patient via telephone interview at 12 months.
Due to appointment availability the six week clinic visit
may actually vary from four to twelve weeks followingthe intervention; this window is seen as clinically
relevant.
Participants
The target population will be patients referred to colla-
borating centres for treatment of haemorrhoids. 350 par-
ticipants will be recruited from surgical departments in
up to 14 NHs hospitals. Adults aged 18 years or over
with symptomatic second or third degree haemorrhoids,
either presenting for the first time or after one failure of
RBL will be eligible to take part in the research.
Exclusion criteria
Patients with certain pre-existing medical conditions will
be excluded: patients with known perianal sepsis, in-
flammatory bowel disease, colorectal malignancy, pre-
existing sphincter injury, or an immunodeficiency. Preg-
nant women and patients that are unable to have general
or spinal anaesthetic are excluded as well as patients
currently taking certain medication: Warfarin, Clopido-
grel and Nicorandil.
Patients that are unable to give full informed consent
(this may be due to mental capacity or language barriers)
and patients previously randomised to this trial will be
excluded from taking part in the research.
Proposed sample size
Assuming the proportion of patients who experience re-
currence following RBL is 30% and following HAL is
15%, the sample size required to detect a difference in
recurrence rates with 80% power and 5% significance is
121 individuals per group. In order to account for any
between-surgeon variation and loss to follow-up, we
propose increasing this to 175 per group. This increase
is based on the conservative assumption that there will
be 14 surgeons in the trial (one per centre) and intra-
class correlation (ICC) of 2.5% in keeping with typical
ICCs observed by Ukoumunne [21]. A more likely sce-
nario is that each site will have a minimum of two sur-
geons, in which case the power to detect this difference
is 85%; if there is no between-surgeon variation, the
power will be 90%. Because the surgical procedure is
well-developed and standardised, intra-class correlation
should be virtually zero and the proposed sample size
should have closer to 90% power.
The impact of loss to follow up will be minimal for
the primary endpoint (haemorrhoidal recurrence at 12
months). Patients who do not complete their 12-month
follow-up will have their hospital notes reviewed and
their GP will be written to in order to ascertain whe-
ther any complications or operative procedures were
recorded. The only drop-out expected would be where
the patient dies, moves out of the area, or has no trace-
able patient notes, and we anticipate this would be less
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population (a previous study of RBL which used only
clinical follow up, reported a 1-year loss to follow up of
10% [22]).
Interventions
The intervention is either RBL or HAL. Both interven-
tions are established and well documented procedures.
Both intervention arms are considered standard care by
NICE.
Conventional RBL uses a simple suction device that is
applied to each haemorrhoid via a disposable proctoscope.
A rubber band is then fired onto the base of the haemor-
rhoid which constricts the blood supply causing it to be-
come ischaemic before being sloughed approximately 1–2
weeks later. The resultant fibrosis reduces any element of
haemorrhoidal prolapse that may have been present. This
is a very commonly performed procedure in all SOPCs;
figures from an audit of current practice at STH over 20
such procedures are carried out every week. The proced-
ure is a basic surgical skill that all senior staff are familiar
with and competent in performing.
HAL uses a proctoscope modified to incorporate a
Doppler transducer. This enables accurate detection of
the haemorrhoidal arteries feeding the haemorrhoidal
cushions. Accurate ligation of the vessels with a suture
reduces haemorrhoidal engorgement. When combined
with a ‘pexy’ suture, both bleeding and haemorrhoidal
prolapse is addressed. All surgeons participating in the
trial will ensure the need for a pexy suture is routinely
assessed and recorded.
The procedure is simple, uses existing surgical skills
and has a short learning curve, with the manufacturers
recommending at least 5 mentored cases before inde-
pendently practising. All surgeons involved in the study
will have completed this training and will have carried
out over 5 procedures prior to recruiting to the study.
Safety Assessments
We will collect data on related Adverse Events (AEs) on
the Case Report Forms (CRFs). Where these events be-
come Serious Adverse Events (SAEs) they will be
reported in accordance with the CTRU’s and the spon-
sor’s Standard Operating Procedures (SOPs). These
SOPs have been developed to comply with guidance
from the National Research Ethics Service, which is a
subdivision of the National Patient Safety Agency, and
Good Clinical Practice (GCP). Site staff will be respon-
sible for reporting SAEs; on identification they will
complete an SAE form and send it to the CTRU and en-
sure that the local Principal Investigator has been
informed.
Details of any related AEs will be recorded on the case
report forms and participant completed questionnairesand reported periodically to the Sponsor, Data Monitor-
ing Committee (DMEC) and the Trial Steering Commit-
tee (TSC). SAEs related to the intervention and
unexpected will be reported Sponsor and expedited to
the Research Ethics Committee (REC) within 15 days of
becoming aware.
Objectives
The primary research question is does haemorrhoidal ar-
tery ligation have a lower recurrence rate than rubber
band ligation when used to treat second and third de-
gree haemorrhoids?
The secondary research questions are which of the
two procedures is more cost-effective; which is least
painful; which has fewest complications and which has
the greatest effect on the patients’ quality of life?
Outcomes
The primary outcome measure is ‘recurrence’, defined as
the proportion of patients with recurrent haemorrhoids
at 12 months, as derived from a telephone assessment in
combination with GP and hospital records.
The trial is a pragmatic design with a dichotomous
outcome. As no validated symptom score exists, we have
based our definition of recurrence on Shanmugam
et al.’s systematic review [6] definition:
1. Cured or improved: Symptom free or mild residual
symptoms but not requiring further treatment at the
end of study period; or,
2. Unchanged or worse: No symptom improvement and
requiring further intervention or suffered
complication or deterioration of symptoms.”
This study will simplify Shanmugam's criteria into the
following question, asked at 12 months by a research
nurse:
‘At the moment, do you feel your symptoms from your
haemorrhoids are:
1. Cured or improved compared with before starting
treatment; or,
2. Unchanged or worse compared with before starting
treatment?’
Any patient who answers ‘1’ but has required further
treatment since the initial procedure will be reclassified
as ‘2’, identified via hospital records, their consultant,
their GP and patient questioning.
Secondary outcome measures:
1. Symptom score (adapted from Nystrom et al. [23])
2. Health related quality of life (using the EuroQol-5D
“The EuroQoL group” [24])
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Incontinence Score [25])
4. Pain score (using a 10 cm visual analogue scale)
5. Surgical complications
6. Need for further treatment including details
7. Clinical appearance of haemorrhoids at proctoscopy
following recurrence
8. Health care costs
9. Cost effectiveness
Eligible patients who have given written informed con-
sent to participate in the study will undergo baseline as-
sessment immediately before randomisation (Symptom
score, EQ-5D, Continence questionnaire). After their
procedure, patients will be asked to complete question-
naires one, seven and twenty-one days after surgery
(EQ-5D, Pain score). At six weeks, further data will be
collected at the routine follow-up clinic visits (Symptom
score, EQ-5D, Pain score, Health and social care re-
source use questionnaire, Complications review inter-
view, Need for further treatment questionnaire). Final-
ly, one year after their procedure, they will be sent
questionnaires (Symptom score, EQ-5D, Continence ques-
tionnaire, Health and social care resource use question-
naire, Complications review interview, Need for further
treatment questionnaire, Recurrence) and be followed up
by telephone. We will measure recurrence (the primary
outcome) at 12 months.
Statistical and Health Economic analyses
Differences in the primary outcome, recurrence of hae-
morrhoids between the two treatment groups, will be
analysed using logistic regression adjusting for sex, age
at surgery and history of previous intervention as fixed
effect covariates and surgeon as a random effect. This
permits the calculation of odds ratios and their confi-
dence intervals for the effect of HAL relative to trad-
itional RBL adjusting for the effects of covariates and the
clustering by surgeon. Further detailed analysis of haem-
orrhoid recurrence will be performed by analysing the
length of time to recurrence under a Cox-proportional
hazards model adjusting for the same covariates. The
secondary outcome of pain, as measured on the visual
analogue scale (VAS), with repeated measures will be
analysed under a multi-level longitudinal approach
adjusting for the same covariates. The secondary out-
come of procedural complications elicited during the
complications review or from the patient notes at 6
weeks and one year post surgery, will be compared bet-
ween the two groups at each time point using Poisson
regression which accounts for the essentially random na-
ture with which complications arise, although care will
be taken to note whether there is any clustering by sur-
geon. The emphasis of all analyses will be on estimatingeffect sizes of HAL surgery on recurrence rates and
other outcomes in comparison to standard treatment
with RBL, and as such appropriate confidence intervals
will be reported for all estimates.
We will collect data as part of the trial that will allow
us to conduct a full economic evaluation. The main eco-
nomic analysis will focus on estimating the incremental
cost per quality adjusted life year (QALY) of HAL versus
RBL over the 12 month follow up period of the trial in:
a) patients with new haemorrhoids; and, b) patients with
recurrence following RBL. We will also present results
in terms of the incremental cost per recurrence avoided.
The time horizon compares to 12 months used in an
evaluation of SH versus RBL in patients with grade II
haemorrhoids conducted alongside a pilot clinical trial
[26] and 3 years in a modelling study comparing SH and
OH [2]. The former study recommended larger trials
and longer follow up. Since it is likely that both surgical
complications and recurrence rates will differ at 12
months we will also use decision modelling to extrapo-
late beyond the trial outcomes. We will draw on and de-
velop as appropriate the model reported in the HTA
report [2]. This model is also being considered for adap-
tation alongside a model that includes RBL, by those
conducting the eTHoS trial (HTA 08/24/02) of stapled
haemorrhoidopexy (SH) vs. traditional haemorrhoidect-
omy (OH). We will liaise with the eTHoS project team
to ensure consistency, where appropriate, in our
approaches to model adaptation. This will include issues
around both model structure and time horizon, as well
as parameter values where these are common to both
decision problems. This will also avoid unnecessary du-
plication of workload, particularly in relation to
reviewing.
Patients will be asked to complete the EQ-5D instru-
ment at baseline and 1 day, 7 days, 21 days, 6 weeks and
12 months following the treatment. The UK population
tariffs will then be used to calculate QALYs for each pa-
tient. EQ-5D has been applied in previous studies in this
area [26] and appears to be sensitive to changes in pa-
tient outcomes. Pain is likely to be one of the main
symptoms in which we might expect the treatments to
differ and this is well reflected in the EQ-5D instrument.
In addition, we will explore the relationship between
EQ-5D values and specific complications and symptoms,
such as relapse, incontinence and pain. We will also
consider the relationship between EQ-5D and the com-
bined symptom severity score. These explorations may
prove valuable to future modelling studies in this area as
there is evidence that previous studies have been ham-
pered by limited utility data. Indeed, a specific recom-
mendation of a recent HTA study was “that further
research should include RCTs which collect a generic
HRQoL measure such as the EQ-5D or SF-36 at follow-
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calculate an estimate of preference-based utility. Baseline
data from a trial of this kind would also provide a better
estimate of HRQoL and utility of patients with symp-
toms.” (p.88 HTA report [2])
We will use appropriate statistical techniques to reflect
skewness, repeated measures from individual patients
and the clustering of the patients, by surgeon and within
different centres. Parameter uncertainty will be fully
reflected in the estimates by generating a cost effective-
ness acceptability curve. We will also consider other
forms of sensitivity analysis to reflect further sources of
uncertainty.
Ethical approval
This research has been approved by South Yorkshire
REC.
Discussion
Alongside the eTHoS trial (HTA 08/24/02) the findings
of the research will help inform future practice for the
treatment of grade II and III haemorrhoids. The results
will enable clinicians to provide patients with up-to-date,
robust information so that they can make an informed
choice of the treatment option most appropriate to their
individual needs. Our findings will be disseminated
through the Association of Coloproctology of Great Brit-
ain and Ireland.
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